PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.96%
Revenue growth near Drug Manufacturers - Specialty & Generic median of 0.92%. Charlie Munger might attribute this to overall industry trends.
-116.90%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
1962.12%
EBIT growth of 1962.12% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
1962.12%
Operating income growth of 1962.12% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that can expand.
-1159.97%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is -10.20%. Seth Klarman would investigate factors dragging net income down.
-1118.10%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is -0.31%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-1118.10%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is -3.13%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
4.74%
Share change of 4.74% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if the modest difference matters long-term.
4.12%
Diluted share change of 4.12% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
55.76%
OCF growth of 55.76% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
48.79%
FCF growth of 48.79% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
773.51%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.29%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
-31.54%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 9.77%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-3473.12%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-20076.82%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
36.10%
3Y OCF/share growth of 36.10% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-17455.75%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-5049.26%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-1634.83%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
8676.79%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 60.27% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
394.53%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 12.48%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
44.47%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 7.84%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.62%
AR growth of 4.62% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-10.16%
Decreasing inventory while Drug Manufacturers - Specialty & Generic is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-6.35%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-9.02%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-14.88%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
-67.07%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
3.79%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.